Last reviewed · How we verify
F# PF-004390 Eye Drops
PF-004390 is a selective TRPM8 antagonist that blocks cold-sensing ion channels in the eye to reduce ocular pain and discomfort.
PF-004390 is a selective TRPM8 antagonist that blocks cold-sensing ion channels in the eye to reduce ocular pain and discomfort. Used for Dry eye disease (ocular surface pain).
At a glance
| Generic name | F# PF-004390 Eye Drops |
|---|---|
| Sponsor | Johnson & Johnson Consumer Inc. (J&JCI) |
| Drug class | TRPM8 antagonist |
| Target | TRPM8 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
TRPM8 (Transient Receptor Potential Melastatin 8) is a cold-sensing ion channel expressed on sensory nerve fibers in the cornea and conjunctiva. By antagonizing TRPM8, PF-004390 reduces neuropathic signaling associated with dry eye disease and ocular surface pain, providing symptomatic relief without affecting tear production or other ocular functions.
Approved indications
- Dry eye disease (ocular surface pain)
Common side effects
- Dysgeusia (taste disturbance)
- Eye irritation
- Conjunctival hyperemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F# PF-004390 Eye Drops CI brief — competitive landscape report
- F# PF-004390 Eye Drops updates RSS · CI watch RSS
- Johnson & Johnson Consumer Inc. (J&JCI) portfolio CI